Positive Patient Stories™

Paratek Pharmaceuticals News

Keyword Search
2019 | 2018 | 2017 | 2016 | 2015
12/03/15Paratek Expands Leadership Team 
11/12/15Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results 
11/09/15Paratek Initiates Omadacycline Phase 3 Clinical Study in Community Acquired Bacterial Pneumonia (CABP) 
11/05/15Paratek Pharmaceuticals to Report Third Quarter 2015 Financial Results on November 12, 2015 
11/04/15Paratek Receives FDA Fast Track Designation for Omadacycline 
10/01/15Paratek Expands Leadership Team With Two New Hires 
09/02/15Paratek Pharmaceuticals, Inc. Announces Participation in Ladenburg Thalmann 2015 Healthcare Conference 
08/05/15Paratek Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial and Operating Results 
08/03/15Paratek Pharmaceuticals to Present Data at ICAAC 2015 
07/28/15Paratek Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 5, 2015 
07/24/15Paratek Announces Termination of Tax Benefit Preservation Plan 
07/22/15Timothy Franson M.D. Joins Paratek's Board of Directors 
07/21/15Paratek Pharmaceuticals Opens New Corporate Headquarters in Boston 
07/01/15Paratek Hires William Haskel as Senior Vice President, General Counsel and Corporate Secretary 
06/23/15Paratek Doses First Patient in Phase 3 Clinical Trial of Omadacycline in Acute Bacterial Skin and Skin Structure Infections 
06/22/15Paratek Set to Join Russell 3000(R) and Russell Global Indexes 
06/17/15Paratek Pharmaceuticals to Present at Upcoming Banking Conferences 
06/11/15Paratek Pharmaceuticals Opens Philadelphia Office 
06/03/15Paratek Pharmaceuticals Strengthens Senior Leadership Team 
05/15/15Paratek Pharmaceuticals, Inc. Reports First Quarter 2015 Financial and Operating Results 
05/05/15Paratek Announces Closing of Common Stock Offering 
04/29/15Paratek Announces Pricing of Public Offering of 2,860,000 Shares of Common Stock 
04/27/15Paratek Announces Proposed Public Offering of Common Stock 
04/02/15Paratek Pharmaceuticals, Inc. Reports Full Year 2014 Financial and Operating Results 
03/12/15Paratek Pharmaceuticals to Present at Two Upcoming Investor Conferences 
02/23/15Paratek Pharmaceuticals to Present at the Cowen Healthcare Conference 
02/10/15Paratek Pharmaceuticals Adopts Inducement Equity Incentive Plan Under NASDAQ Listing Rule 5635(c)(4) 
02/10/15Paratek Pharmaceuticals to Present at the Leerink Global Healthcare Conference 
01/06/15Paratek to Receive $4 Million Payment From Actavis With Initiation of Phase 3 Trial of Sarecycline 

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.